Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
Nutr Metab Cardiovasc Dis
; 26(5): 380-6, 2016 05.
Article
in En
| MEDLINE
| ID: mdl-27067162
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
United States Food and Drug Administration
/
Blood Glucose
/
Adamantane
/
Adverse Drug Reaction Reporting Systems
/
Dipeptidyl Peptidase 4
/
Diabetes Mellitus, Type 2
/
Dipeptides
/
Dipeptidyl-Peptidase IV Inhibitors
/
Sitagliptin Phosphate
/
Heart Failure
Type of study:
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Limits:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
America do norte
/
Asia
/
Europa
Language:
En
Journal:
Nutr Metab Cardiovasc Dis
Journal subject:
ANGIOLOGIA
/
CARDIOLOGIA
/
CIENCIAS DA NUTRICAO
/
METABOLISMO
Year:
2016
Type:
Article
Affiliation country:
Italy